Mosunetuzumab (Lunsumio®). HTA ID: 23023

Assessment Status Full HTA submission received from Applicant
HTA ID 23023
Drug Mosunetuzumab
Brand Lunsumio®
Indication Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Assessment Process
Rapid review commissioned 27/04/2023
Rapid review completed 25/05/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mosunetuzumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/05/2023
Pre-submission consultation with Applicant 04/07/2023
Full submission received from Applicant 22/02/2024